Alpha-Terpineol

Alpha-Terpineol

SCHEMBL901351

CC1=CCC(C(C)(C)O)CC1.CC1=CCC(C(C)(C)O)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
CES2 O00748 3/20 0.59
CYP3A4 P08684 2/20 0.55
ALOX15 P16050 2/20 0.55
STAT3 P40763 2/20 0.55
MEN1 O00255 1/20 0.55
MAPK1 P28482 1/20 0.55
KMT2A Q03164 1/20 0.55
CHRNA7 P36544 1/20 0.55
PTPN1 P18031 1/20 0.44
TAS2R46 P59540 4/20 0.33
TAS2R31 P59538 2/20 0.33
TAS2R10 Q9NYW0 2/20 0.33
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Terpineol SCHEMBL10925321 1.00 LMNA (1.00) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL891812 1.00 LMNA (1.00) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL980991 1.00 LMNA (1.00) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL28466 1.00 LMNA (1.00) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL9562893 0.98 LMNA (0.96) LMNACES2CYP3A4ALOX15STAT3
Nephthenol SCHEMBL14828377 0.93 LMNA (0.86) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL9706032 0.93 LMNA (0.86) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL11682479 0.89 LMNA (0.80) LMNACES2CYP3A4ALOX15STAT3
Alpha-Terpineol SCHEMBL8146925 0.85 LMNA (0.73) LMNACES2CYP3A4ALOX15STAT3
SCHEMBL5708608 0.83 LMNA (0.71) LMNACES2CYP3A4ALOX15STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0565159-B1 8-Hydroxycymene preparation by dehydrogenation QUEST INT (NL) 1996-08-14 EP claimed
EP-0417825-B1 Cymenol preparation by direct dehydrogenation QUEST INT (NL) 1993-10-27 EP claimed
CN-117651500-A Vaporizable material for aerosol generating devices 日本烟草国际股份有限公司 2024-03-05 CN disclosed
WO-2019034614-A1 PSEUDOTSUGA MENZIESII EXTRACT, METHOD FOR OBTAINING SAME AND USE THEREOF CENTRE DE VALORISATION AGRO RESSOURCES (FR) 2019-02-21 WO disclosed
EP-3307393-A1 FRAGRANCE COMPOSITION The Procter and Gamble Company (US) 2018-04-18 EP disclosed
EP-3307231-A1 FRAGRANCE COMPOSITIONS AND USES THEREOF The Procter and Gamble Company (US) 2018-04-18 EP disclosed
EP-3307394-A1 FRAGRANCE FIXATIVES AND COMPOSITIONS COMPRISING THEREOF The Procter and Gamble Company (US) 2018-04-18 EP disclosed
WO-2016205301-A1 FRAGRANCE FIXATIVES AND COMPOSITIONS COMPRISING THEREOF THE PROCTER & GAMBLE COMPANY (US) 2016-12-22 WO disclosed
WO-2016200759-A1 FRAGRANCE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2016-12-15 WO disclosed
WO-2016200761-A2 FRAGRANCE COMPOSITIONS AND USES THEREOF THE PROCTER & GAMBLE COMPANY (US) 2016-12-15 WO disclosed
WO-2016200760-A1 FRAGRANCE COMPOSITIONS AND USES THEREOF THE PROCTER & GAMBLE COMPANY (US) 2016-12-15 WO disclosed
US-20140350121-A1 ANTIMICROBIAL COMPOSITION DOW GLOBAL TECHNOLOGIES LLC 2014-11-27 US disclosed
EP-2621462-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR The Procter and Gamble Company (US) 2013-08-07 EP disclosed
WO-2012044728-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR THE PROCTER & GAMBLE COMPANY (US) 2012-04-05 WO disclosed
WO-2011127011-A1 ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2011-10-13 WO disclosed
WO-2011127030-A1 ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2011-10-13 WO disclosed
WO-2010117740-A2 ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROL TYRATECH, INC. (US) 2010-10-14 WO disclosed
WO-2010115065-A2 METHODS FOR PEST CONTROL EMPLOYING MICROEMULSION-BASED ENHANCED PEST CONTROL FORMULATIONS TYRATECH, INC. (US) 2010-10-07 WO disclosed
WO-2009117621-A1 PEST CONTROL COMPOSITIONS AND METHODS TYRATECH, INC. (US) 2009-09-24 WO disclosed
WO-2007038524-A2 COCRYSTALLIZATION METHODS SSCI, INC. (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350121-A1 ANTIMICROBIAL COMPOSITION TAS2R40, TAS2R39, POLR1C LMNA 3949/4885CES2 2400/4885CYP3A4 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.